AOU finalises long-awaited sale of its Manica Gold Project

|

Published 21-NOV-2017 14:02 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Auroch Minerals (ASX:AOU), a junior metals explorer based in Australia, has confirmed it has received A$1.1 million in cash following the previously agreed sale of the Manica Gold Project to Xtract Resources. Auroch is also due to receive a further A$500,000 before the end of 2017 when Xtract completes its current capital raising scheme aiming to raise £1.53 million in the UK.

In commenting on today’s announcement, AOU’s Executive Chairman, Glenn Whiddon said, “The receipt of the funds has maintained our [Auroch’s] healthy cash balance and these funds will continue to fund the ongoing exploration activities of the Company’s projects and the evaluation of new opportunities.”

AOU chose to shift its explorational focus from gold to lithium in mid-2016, but is also progressing several other metals projects including copper, zinc and cobalt prospects globally.

Earlier this year, Whiddon played an instrumental role to impose several punitive conditions on Xtract, following its failure to provide the entirety of the agreed A$2.5 million sale price for the Manica Gold Project.

Under the terms of the agreement, the two companies have agreed to structure a A$990,000 convertible note and A$1.3 million loan agreement from Auroch to Xtract. If Xtract commits a material breach of the agreed terms, AOU will gain the right to convert its shares at a discount of 30 per cent, as opposed to the agreed 15 per cent. AOU also stands to receive a 3 per cent royalty fee from Xtracts production at Manica.

Deployment of Auroch’s strong capital position

Auroch’s business activities are currently focused on progressing its proprietary “Global Renewable Energy” strategy — a means of building a portfolio of quality assets with specific focus on commodities considered crucial to the renewable energy industry and energy storage.

AOU is placing particular emphasis on cobalt and lithium projects, leveraging two relatively new commodities used in the production of lithium-ion batteries.

It should be noted here that AOU is still an early stage play and investors should seek professional financial advice if considering this stock for their portfolio.

The funds obtained from the sale of its Manica Gold Project, as well as supplementary fundraising efforts, empower AOU to pursue exploration in various regions globally including the Tisova Project in the Czech Republic, the Alcoutim Project in Portugal and the Karibib Project in Namibia.

AOU share price chart

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.

At the time of writing, Auroch shares were trading at $0.245 per share, thereby valuing the company at $22 million by market capitalisation.

AOU continues to develop its other metals projects in various countries. It’s currently undertaking an initial drilling program at its Tisová Cobalt Copper Gold Project (option to acquire 100%) in the Czech Republic.

tags

GOLD


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X